Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280683 · ClinicalTrials.gov registry record · Phase 2
Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma
A Phase 2 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00280683 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 20 participants.
The verdict
NCT00280683, a Phase 2 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma. The investigators believe that a natural amino acid, L-arginine, that augments nitric oxide levels can decrease asthma exacerbations and improve the asthma care of moderate to severe asthma patients. This study is a randomized, placebo controlled trial in which subjects will receive either 3 months of L-arginine supplementation or a placebo. The investigators will monitor subjects' symptoms, the number of asthma exacerbations, and lung function. In addition, we will draw blood, obtain induced sputum samples and measure exhaled breath nitric oxide levels at each monthly visit.
Interventions
- DRUG Placebo
- DRUG L-arginine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280683
The ClinicalTrials.gov registry entry for NCT00280683 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00280683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00280683 about?
NCT00280683 is a clinical study titled "Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma". Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma. The investigators believe that a natural amino acid, L-arginine, that augments nitric oxide levels can decrease asthma exacerbations and improve t...
What is the current status of trial NCT00280683?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2004-12. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00280683?
The interventions under investigation include: Placebo (DRUG), L-arginine (DRUG).
Who is sponsoring clinical trial NCT00280683?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.